158 related articles for article (PubMed ID: 38343077)
1. Precision medicine in cardiovascular therapeutics: Evaluating the role of pharmacogenetic analysis prior to drug treatment.
Ingelman-Sundberg M; Pirmohamed M
J Intern Med; 2024 May; 295(5):583-598. PubMed ID: 38343077
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenomics implementation in cardiovascular disease in a highly diverse population: initial findings and lessons learned from a pilot study in United Arab Emirates.
Al-Mahayri ZN; Khasawneh LQ; Alqasrawi MN; Altoum SM; Jamil G; Badawi S; Hamza D; George L; AlZaabi A; Ouda H; Al-Maskari F; AlKaabi J; Patrinos GP; Ali BR
Hum Genomics; 2022 Sep; 16(1):42. PubMed ID: 36154845
[TBL] [Abstract][Full Text] [Related]
3. Systematic review of the evidence on the cost-effectiveness of pharmacogenomics-guided treatment for cardiovascular diseases.
Zhu Y; Swanson KM; Rojas RL; Wang Z; St Sauver JL; Visscher SL; Prokop LJ; Bielinski SJ; Wang L; Weinshilboum R; Borah BJ
Genet Med; 2020 Mar; 22(3):475-486. PubMed ID: 31591509
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetics and cardiovascular disease--implications for personalized medicine.
Johnson JA; Cavallari LH
Pharmacol Rev; 2013 Jul; 65(3):987-1009. PubMed ID: 23686351
[TBL] [Abstract][Full Text] [Related]
5. Expanding role of pharmacogenomics in the management of cardiovascular disorders.
Yip VL; Pirmohamed M
Am J Cardiovasc Drugs; 2013 Jun; 13(3):151-62. PubMed ID: 23579966
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetics of clopidogrel and warfarin in the treatment of cardiovascular diseases: an overview of reviews.
de Lara DV; de Melo DO; Araújo Silva LC; Gonçalves TS; Júnior Lima Santos PC
Pharmacogenomics; 2022 May; 23(7):443-452. PubMed ID: 35380455
[TBL] [Abstract][Full Text] [Related]
7. Applied pharmacogenomics in cardiovascular medicine.
Weeke P; Roden DM
Annu Rev Med; 2014; 65():81-94. PubMed ID: 24111889
[TBL] [Abstract][Full Text] [Related]
8. Projected impact of a multigene pharmacogenetic test to optimize medication prescribing in cardiovascular patients.
Dong OM; Li A; Suzuki O; Oni-Orisan A; Gonzalez R; Stouffer GA; Lee CR; Wiltshire T
Pharmacogenomics; 2018 Jun; 19(9):771-782. PubMed ID: 29793377
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness of Multigene Pharmacogenetic Testing in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention.
Dong OM; Wheeler SB; Cruden G; Lee CR; Voora D; Dusetzina SB; Wiltshire T
Value Health; 2020 Jan; 23(1):61-73. PubMed ID: 31952675
[TBL] [Abstract][Full Text] [Related]
10. Analytics of the clinical implementation of pharmacogenomics testing in 12 758 individuals.
Wang Y; Xiao F; Chen Y; Xiao LD; Wang LY; Zhan Y; Xiong XL; Zhou G; Liu R; Ouyang DS; Li Z; McLeod HL; Zhang W; Li Q; Liu ZQ; Zhou HH; Yin JY
Clin Transl Med; 2021 Nov; 11(11):e586. PubMed ID: 34841710
[No Abstract] [Full Text] [Related]
11. Genotype-guided warfarin therapy: current status.
Tavares LC; Marcatto LR; Santos PCJL
Pharmacogenomics; 2018 May; 19(7):667-685. PubMed ID: 29701078
[TBL] [Abstract][Full Text] [Related]
12. Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementation.
Ong FS; Deignan JL; Kuo JZ; Bernstein KE; Rotter JI; Grody WW; Das K
Pharmacogenomics; 2012 Mar; 13(4):465-75. PubMed ID: 22380001
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetics in the Treatment of Cardiovascular Diseases and Its Current Progress Regarding Implementation in the Clinical Routine.
Dávila-Fajardo CL; Díaz-Villamarín X; Antúnez-Rodríguez A; Fernández-Gómez AE; García-Navas P; Martínez-González LJ; Dávila-Fajardo JA; Barrera JC
Genes (Basel); 2019 Apr; 10(4):. PubMed ID: 30939847
[TBL] [Abstract][Full Text] [Related]
14. A model-based cost-effectiveness analysis of pharmacogenomic panel testing in cardiovascular disease management: preemptive, reactive, or none?
Zhu Y; Moriarty JP; Swanson KM; Takahashi PY; Bielinski SJ; Weinshilboum R; Wang L; Borah BJ
Genet Med; 2021 Mar; 23(3):461-470. PubMed ID: 33041335
[TBL] [Abstract][Full Text] [Related]
15. Recent developments and future directions for the use of pharmacogenomics in cardiovascular disease treatments.
Berinstein E; Levy A
Expert Opin Drug Metab Toxicol; 2017 Sep; 13(9):973-983. PubMed ID: 28792790
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular Pharmacogenomics--Implications for Patients With CKD.
Cavallari LH; Mason DL
Adv Chronic Kidney Dis; 2016 Mar; 23(2):82-90. PubMed ID: 26979147
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenomic profile of a central European urban random population-Czech population.
Proietti R; Maranho Neto GA; Kunzova S; Lo Re O; Ahola-Olli A; Heliste J; Gonzalez-Rivas JP; Vinciguerra M
PLoS One; 2023; 18(4):e0284386. PubMed ID: 37079615
[TBL] [Abstract][Full Text] [Related]
18. Clinical pharmacogenomics of warfarin and clopidogrel.
Shin J
J Pharm Pract; 2012 Aug; 25(4):428-38. PubMed ID: 22674970
[TBL] [Abstract][Full Text] [Related]
19. Role of CYP4F2, CYP2C19, and CYP1A2 polymorphisms on acenocoumarol pharmacogenomic algorithm accuracy improvement in the Greek population: need for sub-phenotype analysis.
Ragia G; Karantza IM; Kelli-Kota E; Kolovou V; Kolovou G; Konstantinides S; Maltezos E; Tavridou A; Tziakas D; Maitland-van der Zee AH; Manolopoulos VG
Drug Metab Pers Ther; 2017 Dec; 32(4):183-190. PubMed ID: 29252193
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular Pharmacogenomics: An Update on Clinical Studies of Antithrombotic Drugs in Brazilian Patients.
Hirata TDC; Dagli-Hernandez C; Genvigir FDV; Lauschke VM; Zhou Y; Hirata MH; Hirata RDC
Mol Diagn Ther; 2021 Nov; 25(6):735-755. PubMed ID: 34357562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
